Population with Chronic Obstructive Pulmonary Disease in US Primary Care


For one study, researchers sought to describe the demographic and clinical characteristics of patients with chronic obstructive pulmonary disease (COPD) cared for in primary care in the United States. The Optimum Patient Care DARTNet COPD Research Database, which served as the basis for the Advancing the Patient Experience COPD Registry, provided the data for the registry’s observational study. Patients enrolled in the registry had reached the age of 35 or older at the time of diagnosis. Electronic health record data was obtained from registries and patient-reported information and outcomes from the Advancing the Patient Experience Registry from 5 primary care groups in Texas, Ohio, Colorado, New York, and Carolina du Nord (from June 2019 to November 2020). Of the 17,192 patients included, 1,354 were registered in the Advancing the Patient Experience registry. The majority of patients were female (56%; 9,689/17,192), white (64%; 9,732/15,225), current/ex-smokers (80%; 13,784/17,192) and people in overweight/obese (69%; 11,689/16,849) . Inhaled corticosteroids with a long-acting β2-agonist (30%) and inhaled corticosteroids with a long-acting muscarinic antagonist were the most frequently prescribed maintenance treatments (27%). Although 3% (565/17,192) of patients were untreated, 9% (1,587/17,192) were receiving a short-acting bronchodilator monotherapy and 4% (756/17,192) were receiving inhaled corticosteroid therapy monotherapy. Despite treatment, 38% (6,579/17,192) of patients experienced 1 or more exacerbations in the past 12 months. Many patients reported a high or very high impact of illness on their health in the Advancing Patient Experience Registry (43%; 580/1322), a shortness of breath score of 2 or greater (45%; 588/1315 ) and 1 or more exacerbations in the last 12 months (50%; 646/1294). The results highlighted the significant exacerbation, symptoms, and treatment burdens of COPD patients in the United States and the need for further real-world efficacy trials to aid decision-making regarding primary care.

Source – annfammed.org/content/20/4/319


Comments are closed.